- Home
- PHAR vs ECPG Comparison
PHAR vs ECPG Comparison
Compare PHAR & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ECPG
- Stock Information
- Founded
- PHAR 1988
- ECPG 1998
- Country
- PHAR Netherlands
- ECPG United States
- Employees
- PHAR N/A
- ECPG N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ECPG Finance Companies
- Sector
- PHAR Health Care
- ECPG Finance
- Exchange
- PHAR Nasdaq
- ECPG Nasdaq
- Market Cap
- PHAR 951.7M
- ECPG 905.2M
- IPO Year
- PHAR N/A
- ECPG 1999
- Fundamental
- Price
- PHAR $13.14
- ECPG $40.90
- Analyst Decision
- PHAR Strong Buy
- ECPG Strong Buy
- Analyst Count
- PHAR 3
- ECPG 3
- Target Price
- PHAR $30.00
- ECPG $62.67
- AVG Volume (30 Days)
- PHAR 11.0K
- ECPG 253.4K
- Earning Date
- PHAR 11-06-2025
- ECPG 11-05-2025
- Dividend Yield
- PHAR N/A
- ECPG N/A
- EPS Growth
- PHAR N/A
- ECPG N/A
- EPS
- PHAR N/A
- ECPG N/A
- Revenue
- PHAR $339,836,000.00
- ECPG $1,467,587,000.00
- Revenue This Year
- PHAR $17.70
- ECPG $27.55
- Revenue Next Year
- PHAR $12.25
- ECPG $5.84
- P/E Ratio
- PHAR N/A
- ECPG N/A
- Revenue Growth
- PHAR 22.44
- ECPG 15.50
- 52 Week Low
- PHAR $7.31
- ECPG $26.45
- 52 Week High
- PHAR $17.08
- ECPG $51.77
- Technical
- Relative Strength Index (RSI)
- PHAR 42.37
- ECPG 46.16
- Support Level
- PHAR $13.08
- ECPG $41.44
- Resistance Level
- PHAR $14.10
- ECPG $45.30
- Average True Range (ATR)
- PHAR 0.52
- ECPG 1.47
- MACD
- PHAR -0.16
- ECPG -0.09
- Stochastic Oscillator
- PHAR 0.00
- ECPG 37.18
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.